CN111388447A - Adriamycin nano-particles, preparation method and application thereof, and medicine for treating tumors by combining acoustic power with chemical therapy - Google Patents
Adriamycin nano-particles, preparation method and application thereof, and medicine for treating tumors by combining acoustic power with chemical therapy Download PDFInfo
- Publication number
- CN111388447A CN111388447A CN201811615253.4A CN201811615253A CN111388447A CN 111388447 A CN111388447 A CN 111388447A CN 201811615253 A CN201811615253 A CN 201811615253A CN 111388447 A CN111388447 A CN 111388447A
- Authority
- CN
- China
- Prior art keywords
- adriamycin
- solution
- nanoparticles
- polyamino acid
- nanoparticle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
- A61K41/0033—Sonodynamic cancer therapy with sonochemically active agents or sonosensitizers, having their cytotoxic effects enhanced through application of ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides an adriamycin nanoparticle, a preparation method and application thereof, and a medicament for treating tumors by combining acoustic power with chemical therapy, and relates to the technical field of nano medicaments. The adriamycin nanoparticles provided by the invention can improve the biocompatibility and the cell phagocytosis efficiency of adriamycin by loading the adriamycin on the nanoparticle carrier, and can generate active oxygen clusters under the action of ultrasound to inhibit the efflux of adriamycin by tumor cells, so that the drug resistance of tumor cells is overcome, the antitumor therapy of synergy and attenuation is realized, and the adriamycin nanoparticles have wide application prospects in the fields of biomedicine, disease diagnosis and acoustic-dynamic combined chemotherapy.
Description
Technical Field
The invention relates to the field of nano-drugs, in particular to adriamycin nano-particles, a preparation method and application thereof, and a drug for treating tumors by combining acoustic power with chemical therapy.
Background
Adriamycin is a broad-spectrum antineoplastic drug, can inhibit the synthesis of RNA and DNA, and has killing effect on various tumors and tumor cells in various growth cycles. However, doxorubicin has strong toxic and side effects on normal cells, and easily produces a multidrug resistance effect on tumor cells, thereby limiting the application of doxorubicin in tumor treatment.
The rapid development of nanotechnology provides a new idea for solving the problems faced in the doxorubicin chemotherapy process. The nano drug-carrying system can improve the bioavailability and biocompatibility of the adriamycin and regulate the circulation and distribution in vivo, and becomes one of the most effective ways for reducing the toxic and side effects of chemotherapeutic drugs and improving the curative effect of the drugs. At present, the multi-drug resistance problem of the adriamycin is effectively reduced by combining gene therapy, oxygen supply therapy and other modes, but the modes need to deliver the adriamycin, the gene and oxygen to a tumor part to play a role simultaneously, and the clinical application cost is high and the difficulty is high.
In view of the above, the present invention is particularly proposed.
Disclosure of Invention
The invention aims to provide an adriamycin nanoparticle, which solves the technical problems of high clinical application cost and great difficulty of adriamycin multiple drug resistance in the mode of relieving the existing combined gene therapy, oxygen supply therapy and the like.
The adriamycin nanoparticle provided by the invention comprises adriamycin and a nanoparticle carrier, wherein the adriamycin is loaded on the nanoparticle carrier.
Further, the nanoparticle carrier is selected from at least one of liposome, polyamino acid nanoparticle, polylactic acid-glycolic acid nanoparticle, gold nanocage and mesoporous silicon, and is preferably polyamino acid nanoparticle.
Furthermore, the particle size of the adriamycin nano particles is 20-150nm, preferably 50-100 nm.
The second purpose of the invention is to provide a preparation method of adriamycin nanoparticles, which comprises the following steps:
uniformly mixing adriamycin and the nanoparticle carrier to enable the adriamycin to be loaded on the nanoparticle carrier to obtain adriamycin nanoparticles;
preferably, the nanoparticle carrier is a polyamino acid nanoparticle.
Further, the preparation method of the adriamycin nano particles comprises the following steps: uniformly mixing a polyamino acid salt solution, an adriamycin solution and a cross-linking agent solution, so that polyamino acid and the cross-linking agent react, fold and cross-link to form polyamino acid nanoparticles, and meanwhile, adriamycin is loaded on the polyamino acid nanoparticles to obtain adriamycin nanoparticles;
preferably, a carboxyl activating agent is added into the polyamino acid solution for carboxyl activation, and then the mixture is uniformly mixed with the adriamycin solution and the cross-linking agent solution;
preferably, the carboxyl activating agent is EDC and/or NHS, preferably EDC and NHS;
further preferably, the mass ratio of EDC and NHS is (5-6): (3-4).
Further, the cross-linking agent is a diamino small molecule cross-linking agent, preferably cystamine dihydrochloride;
and/or, the polyamino acid is selected from one or more of polyglutamic acid, polyaspartic acid, polyalanine, polylysine and polyalanine and salts thereof, and is preferably polyglutamate.
Further, the mass ratio of the polyglutamate to the cystamine dihydrochloride to the adriamycin is (1-3): (2-6): (1-3), preferably 1:2: 1.
Further, the solution of the polyamino acid is a PBS solution of the polyamino acid, and the concentration of the PBS solution of the polyamino acid is (0.5-1.5) mg/m L, preferably 1mg/m L;
and/or the cystamine dihydrochloride solution is a cystamine dihydrochloride PBS solution, and the concentration of the cystamine dihydrochloride PBS solution is (0.5-1.5) mg/m L, preferably 1mg/m L;
and/or the adriamycin solution is a PBS (phosphate buffer solution) of adriamycin, and the concentration of the PBS of the adriamycin is (0.2-0.8) mg/m L, preferably 0.5mg/m L.
The third purpose of the invention is to provide the application of the adriamycin nano-particles or the adriamycin nano-particles obtained by the preparation method provided by the invention in preparing a tumor drug for sonodynamic combination chemotherapy.
The fourth purpose of the invention is to provide a tumor drug for acoustic-dynamic combined chemotherapy, which comprises the adriamycin nano-particles provided by the invention or the adriamycin nano-particles prepared by the preparation method provided by the invention.
The adriamycin nanoparticles provided by the invention can improve the biocompatibility and the cell phagocytosis efficiency of adriamycin by loading the adriamycin on the nanoparticle carrier, can generate active oxygen clusters under ultrasound to inhibit the efflux of adriamycin by tumor cells, and can overcome the drug resistance of the tumor cells without being combined with other substances to be co-delivered to tumor parts, thereby realizing the tumor treatment with synergy and attenuation, reducing the clinical application cost and the treatment difficulty, and having wide application prospects in the fields of biomedicine, disease diagnosis and sound power combined chemical treatment.
The preparation method of the adriamycin nano particles provided by the invention has the advantages of simple process and low raw material cost, and can obviously reduce the preparation cost of the adriamycin nano particles.
Drawings
FIG. 1 is a graph showing the particle size distribution of doxorubicin nanoparticles provided in example 1;
FIG. 2 is a graph of the UV-VIS absorption spectra of doxorubicin nanoparticles provided in example 1 and an aqueous DOX solution provided in comparative example 1;
FIG. 3 is a bar graph of in vitro killing effect of doxorubicin nanoparticles provided in example 1 and aqueous DOX solution provided in comparative example 1 on U87 cells (glioma cells) at different DOX concentrations;
FIG. 4 is a bar graph of in vitro killing effect of the doxorubicin nanoparticles provided in example 1 and the DOX aqueous solution and the blank control provided in comparative example 1 on U87 cells (glioma cells) under the combined action of ultrasound at different DOX concentrations;
FIG. 5 is a graph showing the fluorescence detection effect of the doxorubicin nanoparticles provided in example 1, the DOX aqueous solution provided in comparative example 1 and the deionized water provided in comparative example 2 on the generation of reactive oxygen species under the action of different ultrasonic times;
FIG. 6 is a graph showing the release of doxorubicin nanoparticles provided in example 1 in 24 hours in PBS solution at pH7.4 and PBS solution at pH5.5, respectively.
Detailed Description
Embodiments of the present invention will be described in detail below with reference to examples, but it will be understood by those skilled in the art that the following examples are only illustrative of the present invention and should not be construed as limiting the scope of the present invention. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
It should be noted that:
in the present invention, all the embodiments and preferred methods mentioned herein can be combined with each other to form a new technical solution, if not specifically stated.
In the present invention, the percentage (%) or parts means the weight percentage or parts by weight with respect to the composition, if not otherwise specified.
In the present invention, the components referred to or the preferred components thereof may be combined with each other to form a novel embodiment, if not specifically stated.
In the present invention, unless otherwise stated, the numerical range "a-b" represents a shorthand representation of any combination of real numbers between a and b, where a and b are both real numbers. For example, a numerical range of "6 to 22" means that all real numbers between "6 to 22" have been listed herein, and "6 to 22" is simply a shorthand representation of the combination of these values.
The "ranges" disclosed herein may have one or more lower limits and one or more upper limits, respectively, in the form of lower limits and upper limits.
In the present invention, unless otherwise specified, the individual reactions or operation steps may be performed sequentially or may be performed in sequence. Preferably, the reaction processes herein are carried out sequentially.
Unless otherwise defined, technical and scientific terms used herein have the same meaning as is familiar to those skilled in the art. In addition, any methods or materials similar or equivalent to those described herein can also be used in the present invention.
According to one aspect of the present invention, the present invention provides an doxorubicin nanoparticle comprising doxorubicin and a nanoparticle carrier, said doxorubicin being supported on said nanoparticle carrier.
In the invention, the adriamycin is loaded on the nanoparticle carrier through a chemical bond or an entrapment mode, wherein the chemical bond comprises a covalent bond, an ionic bond and a metal bond.
The adriamycin nanoparticles provided by the invention can improve the biocompatibility and the cell phagocytosis efficiency of adriamycin by loading the adriamycin on the nanoparticle carrier, can generate active oxygen clusters under ultrasound to inhibit the efflux of adriamycin by tumor cells, and can overcome the drug resistance of the tumor cells without being combined with other substances to be co-delivered to tumor parts, thereby realizing the tumor treatment with synergy and attenuation, reducing the clinical application cost and the treatment difficulty, and having wide application prospects in the fields of biomedicine, disease diagnosis and sound power combined chemical treatment.
In a preferred embodiment of the present invention, the nanoparticle carrier includes, but is not limited to, one or more of liposome, polyamino acid nanoparticle, polylactic acid-glycolic acid nanoparticle, gold nanocage and mesoporous silicon. Especially, when the nano-particle carrier is the polyamino acid nano-particle, the nano-particle carrier has higher drug encapsulation rate and entrapment rate, better stability, quick degradation in an acid environment, realization of response release of the drug, good biocompatibility and sound sensitivity, effective reduction of organism toxicity, overcoming of drug resistance of tumor cells and improvement of anti-tumor curative effect.
In a preferred embodiment of the present invention, the adriamycin nanoparticles have a particle size of 20 to 150 nm. The particle size of the adriamycin nano particles is controlled to be 20-100nm, so that the adriamycin nano particles are favorably targeted to tumor cells. If the particle size of the adriamycin nanoparticles is less than 20nm, the adriamycin nanoparticles are easy to agglomerate to form large particles, which are not beneficial to targeting tumor cells, and if the particle size of the adriamycin nanoparticles is more than 150nm, the adriamycin nanoparticles are not beneficial to targeting tumor cells. Especially, when the particle size of the adriamycin nano particles is 50-100nm, the adriamycin nano particles have better targeting property.
Typically, but not by way of limitation, the doxorubicin nanoparticles have a particle size of, for example, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, or 150 nm.
According to a second aspect of the present invention, the present invention provides a method for preparing doxorubicin nanoparticles, comprising the steps of: uniformly mixing the adriamycin and the nanoparticle carrier to load the adriamycin on the nanoparticle carrier to obtain the adriamycin nanoparticles.
In the invention, the adriamycin is loaded on the nanoparticle carrier through chemical bonds or in an entrapment mode, wherein the chemical bonds comprise covalent bonds, ionic bonds and metal bonds.
The preparation method of the adriamycin nano particles provided by the invention has the advantages of simple process and low raw material cost, and can obviously reduce the preparation cost of the adriamycin nano particles.
In a preferred embodiment of the invention, the nanoparticle carrier is a polyamino acid nanoparticle. The selected polyamino acid nano-particles as the adriamycin carrier have the following beneficial effects:
(1) the adriamycin can be efficiently loaded on the polyamino acid nanoparticles to form stable drug-loaded nanoparticles with high encapsulation efficiency and high loading capacity;
(2) the polyamino acid nano-particles have good biocompatibility and biodegradability, and can effectively reduce the toxicity of the adriamycin to organisms;
(3) the polyamino acid nanoparticles can be rapidly degraded under an acidic condition, so that the response control release of the adriamycin is realized;
(4) after the adriamycin is loaded, the compound has sound sensitivity, can generate active oxygen clusters under ultrasonic, overcomes the drug resistance of cancer cells to the adriamycin, and improves the anti-tumor curative effect.
In a preferred embodiment of the present invention, the preparation method of the doxorubicin nanoparticles comprises the following steps: and uniformly mixing the polyamino acid solution, the adriamycin solution and the cross-linking agent solution, so that the polyamino acid and the cross-linking agent react, fold and cross-link to form polyamino acid nanoparticles, and meanwhile, the adriamycin is loaded on the polyamino acid nanoparticles to obtain the adriamycin nanoparticles.
In a preferred embodiment of the present invention, the polyamino acid contains both carboxyl groups and amino groups, and the crosslinking agent crosslinks the amino groups, crosslinks the carboxyl groups, or crosslinks the amino groups and the carboxyl groups, so that the segments of the polyamino acid are folded to form the polyamino acid nanoparticles. The adriamycin contains amino groups, can interact with carboxyl groups of polyamino acid, and is encapsulated in polyamino nanoparticles.
In a preferred embodiment of the present invention, the carboxyl activating agent is added to the polyamino acid solution to activate the carboxyl, and then the mixture is uniformly mixed with the adriamycin solution and the cross-linking agent.
Because the polyamino acid contains both amino and carboxyl, a carboxyl activating agent is added into the polyamino acid solution, so that the carboxyl in the polyamino acid is activated to facilitate the crosslinking reaction of the polyamino acid and a crosslinking agent, the polyamino acid nanoparticles are formed by crosslinking and folding, and meanwhile, the activated carboxyl is also easy to react with the amino in adriamycin, so that the adriamycin is loaded on the polyamino acid nanoparticles through an amido bond.
In a preferred embodiment of the invention, the carboxyl activating agent is EDC and/or NHS.
In a preferred embodiment of the invention, EDC is 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride; NHS for N-hydroxy succinimide.
In a further preferred embodiment of the present invention, when the carboxyl activating agent is a mixture of EDC and NHS, it has a better activating effect on the carboxyl groups in the polyamino acid, and is more favorable for the reaction of the carboxyl groups.
In a further preferred embodiment of the present invention, when the carboxyl activating agent is a mixture of EDC and NHS, and the mass ratio of EDC and NHS is (5-6): (3-4), the activation efficiency of the carboxyl group activator is higher.
Typically, but not by way of limitation, the mass of EDC and NHS in the carboxy activator is, for example, 5:3, 5.2:3, 5.5:3, 5.8:3, 5:3.2, 5.2:3.2, 5.5:3.2, 5.8:3.2, 6:3.2, 5:3.5, 5.2:3.5, 5.5:3.5, 5.8:3.5, 6:3.5, 5:3.8, 5.2:3.8, 5.5:3.8, 5.8:3.8, 6:3.8, 5:4, 5.2:4, 5.5:4, 5.8:4, or 6: 4.
In a preferred embodiment of the invention, the cross-linking agent is a diamino small molecule cross-linking agent. The diamino micromolecules are selected as the cross-linking agent, so that the crosslinking reaction between the diamino micromolecules and activated carboxyl in the polyamino acid is facilitated, and the polyamino acid is folded and crosslinked to form the polyamino acid nano-particles.
In a further preferred embodiment of the present invention, the crosslinking agent is cystamine dihydrochloride, including but not limited to sodium cystamine dihydrochloride, potassium cystamine dihydrochloride, and the like.
In a preferred embodiment of the present invention, the polyamino acid is selected from one or more of polyglutamic acid, polyaspartic acid, polyalanine, polylysine, polyalanine, polyglutamate, polyaspartate, polyalaninate, polylysine salt and polyalanine salt. Especially, when the polyamino acid is polyglutamate, the raw material source is wider, the cost is lower, and the polyamino acid nanoparticles are easier to form.
In a preferred embodiment of the present invention, polyglutamates include, but are not limited to, sodium polyglutamate and potassium polyglutamate, more preferably sodium polyglutamate.
In a preferred embodiment of the present invention, the mass ratio of polyglutamate, cystamine dihydrochloride and doxorubicin is (1-3): (2-6): (1-3), by controlling the mass ratio of the three components, the adriamycin nanoparticles with the particle size of 20-150nm can be conveniently prepared, the encapsulation efficiency and the drug loading rate of the adriamycin can be improved, and particularly, when the mass ratio of the polyglutamate to the cystamine dihydrochloride to the adriamycin is 1:2:1, the drug encapsulation efficiency and the drug loading rate of the prepared adriamycin nanoparticles are higher.
Typically, but not by way of limitation, the masses of polyglutamate, cystamine dihydrochloride and doxorubicin are, for example, 1:2:1, 1:2:2, 1:3:1, 1:3:2, 1:4:1, 1:4:2, 2:2:1, 2:2:2, 2:3:1, 2:3:2, 2:4:1 or 2:4: 2.
In a preferred embodiment of the invention, the solution of the polyamino acid is a PBS solution of the polyamino acid, the concentration of the PBS solution of the polyamino acid being 0.5-1.5mg/m L.
The polyamino acid nanoparticles are prepared by controlling the concentration of the polyamino acid in PBS to facilitate its reaction with the crosslinking agent, particularly to facilitate the formation of polyamino acid nanoparticles when the concentration of the solution of polyamino acid in PBS is 1mg/m L typical, but not limiting, the concentration of the solution of polyamino acid in PBS is, for example, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, or 1.5mg/m L.
In a preferred embodiment of the invention, the pH of the PBS solution of the polyamino acid is 5 to 6, preferably 5.5.
The pH value of the PBS solution of the polyamino acid is controlled to be 5-6, so that the crosslinking reaction of the polyamino acid is facilitated to generate polyamino acid nanoparticles, and the crosslinking reaction is easier to perform especially when the pH value is 5.5. Typically, but not by way of limitation, the pH of the PBS solution of the polyamino acid is, e.g., 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, or 6.
In a preferred practice of the invention, the cystamine dihydrochloride solution is cystamine dihydrochloride PBS solution having a concentration of (0.5-1.5) mg/m L.
The concentration of cystamine dihydrochloride in PBS is controlled to be 0.5-1.5mg/m L to facilitate the crosslinking reaction with polyamino acid, so as to improve the crosslinking efficiency, especially when the concentration of cystamine dihydrochloride in PBS is 0.5-1.5mg/m L, the crosslinking efficiency with polyamino acid is higher.
In a preferred embodiment of the invention, the doxorubicin solution is a PBS solution of doxorubicin, the concentration of the doxorubicin PBS solution being (0.2-0.8) mg/m L, preferably 0.5mg/m L.
In a preferred embodiment of the present invention, doxorubicin is reacted with the polyamino acid and the cross-linking agent in a slight excess amount to facilitate an increase in drug loading of the doxorubicin nanoparticles, which is disadvantageous for the preparation of doxorubicin nanoparticles with high drug loading if the concentration of the PBS solution of doxorubicin is less than 0.2mg/m L, and is more wasteful of doxorubicin if the concentration of the PBS solution of doxorubicin is greater than 0.8mg/m L, so that doxorubicin nanoparticles with high drug loading can be prepared more easily by selecting a PBS solution of doxorubicin with a concentration of 0.2-0.8mg/m L, especially when the concentration of the PBS solution of doxorubicin is 0.5mg/m L.
According to a third aspect of the present invention, the present invention provides the use of the doxorubicin nanoparticles described above or the doxorubicin nanoparticles obtained according to the above preparation method in the preparation of a medicament for sonodynamic combination chemotherapy of tumors.
Such tumors include, but are not limited to, brain glioma, ovarian cancer, endometrial cancer, renal cancer, breast cancer, lung cancer, colon cancer, and nasopharyngeal carcinoma.
According to a fourth aspect of the present invention, the present invention provides an acoustodynamic combined chemotherapy tumor drug, which comprises the doxorubicin nanoparticles provided by the present invention or the doxorubicin nanoparticles obtained according to the preparation method described above.
Such tumors include, but are not limited to, brain glioma, ovarian cancer, endometrial cancer, renal cancer, breast cancer, lung cancer, colon cancer, and nasopharyngeal carcinoma.
The technical solution provided by the present invention is further described below with reference to examples and comparative examples.
Example 1
The embodiment provides an adriamycin nanoparticle, which is prepared according to the following steps:
(1) respectively preparing a PBS (poly-glutamic acid sodium) (PGA), an EDC (polyethylene glycol dimethyl ether) water solution, an NHS (polyethylene glycol dimethyl ether) water solution, a cystamine dihydrochloride (Cys) PBS solution and an adriamycin PBS solution, wherein the concentration of the PGA PBS solution is 1mg/m L, the pH value is 5.5, the concentration of the EDC water solution is 5.2mg/m L, the concentration of the EDC water solution is 3.2mg/m L, the concentration of the Cys PBS solution is 1mg/m L, the concentration of the PBS solution is 0.5mg/m L, and the pH value is 7.4;
(2) 1m L of PBS solution of PGA was added to the solution, 0.5m L EDC aqueous solution and 0.5m L NHS aqueous solution were rapidly dropped into the solution and stirred at room temperature for 15 min;
(3) dropwise adding a 1m L DOX PBS solution and a 1m L Cys PBS solution into the solution obtained in the step (2), and stirring at room temperature for 4h to obtain a nanoparticle solution;
(4) and (4) loading the nanoparticle solution obtained in the step (3) into a dialysis bag with a molecular weight of 3500, and dialyzing with water for 24 hours to obtain the purified adriamycin polyamino acid nanoparticles.
Example 2
This example provides doxorubicin nanoparticles, which are different from example 1 in that in step (1), the concentration of the PBS solution of PGA obtained is 0.5mg/m L, and the rest of the steps are the same as those in example 1, and are not repeated herein.
Example 3
This example provides doxorubicin nanoparticles, which are different from example 1 in that in step (1), the concentration of the PBS solution of PGA obtained is 1.5mg/m L, and the rest of the steps are the same as those in example 1, and are not repeated herein.
Example 4
This example provides an doxorubicin nanoparticle, which is different from example 1 in that in step (1), the concentration of the prepared PBS solution of Cys is 0.5mg/m L, and the rest of the steps are the same as example 1 and are not repeated herein.
Example 5
This example provides an doxorubicin nanoparticle, which is different from example 1 in that in step (1), the concentration of the prepared PBS solution of Cys is 1.5mg/m L, and the rest of the steps are the same as example 1 and are not repeated herein.
Example 6
This example provides doxorubicin nanoparticles, which are different from example 1 in that in step (1), the concentration of the prepared DOX PBS solution is 0.2mg/m L, and the rest of the steps are the same as example 1 and are not repeated herein.
Example 7
This example provides doxorubicin nanoparticles, which are different from example 1 in that in step (1), the concentration of the prepared DOX PBS solution is 0.8mg/m L, and the rest of the steps are the same as example 1 and are not repeated herein.
Example 8
This example provides doxorubicin nanoparticles, which are different from example 1 in that in step (1), the concentration of the PBS solution of PGA obtained is 0.2mg/m L, and the rest of the steps are the same as those in example 1, and are not repeated herein.
Example 9
This example provides doxorubicin nanoparticles, which are different from example 1 in that in step (1), the concentration of the PBS solution of PGA obtained is 3mg/m L, and the rest of the steps are the same as those in example 1, and are not repeated herein.
Example 10
This example provides an doxorubicin nanoparticle, which is different from example 1 in that in step (1), the concentration of the prepared PBS solution of Cys is 0.2mg/m L, and the rest of the steps are the same as example 1 and are not repeated herein.
Example 11
This example provides an doxorubicin nanoparticle, which is different from example 1 in that in step (1), the concentration of the prepared PBS solution of Cys is 3mg/m L, and the rest of the steps are the same as example 1 and are not repeated herein.
Example 12
This example provides doxorubicin nanoparticles, which are different from example 1 in that in step (1), the concentration of the prepared DOX PBS solution is 0.1mg/m L, and the rest of the steps are the same as example 1 and are not repeated herein.
Comparative example 1
This comparative example 1 provides an aqueous solution of DOX.
Comparative example 2
This comparative example 2 provides deionized water.
Test example 1
0.5m L m of the doxorubicin nanoparticle solutions provided in examples 1 to 12 were taken, diluted to appropriate concentrations with PBS solutions, and analyzed with an ultraviolet spectrophotometer to calculate the drug content, and 0.5m L m of the doxorubicin nanoparticle solutions provided in examples 1 to 12 were precisely measured and lyophilized, and the weights of the nanoparticles were weighed and recorded, respectively, to calculate the drug loading rate.
The doxorubicin nanoparticles 0.5m L provided in examples 1 to 12 were each precisely weighed, diluted to an appropriate concentration with PBS solutions, and then analyzed with uv spectrophotometers, respectively, to calculate the total drug content, and to calculate the encapsulation efficiency.
The doxorubicin nanoparticle solutions provided in examples 1-12 were each diluted to the appropriate concentration and the particle size was measured in a malvern laser particle sizer. The results are shown in Table 1.
TABLE 1 doxorubicin nanoparticles data sheet
| Drug Loading Rate (%) | Encapsulation efficiency (%) | Particle size (nm)/PDI | |
| Example 1 | 29.35 | 87.96 | 69.27/0.31 |
| Example 2 | 26.96 | 51.36 | 53.86/0.50 |
| Example 3 | 20.48 | 80.77 | 114.11/0.58 |
| Example 4 | 20.43 | 61.84 | 43.32/0.48 |
| Example 5 | 22.82 | 78.61 | 115.56/0.59 |
| Example 6 | 20.25 | 81.17 | 65.44/0.25 |
| Example 7 | 21.01 | 56.33 | 119.47/0.59 |
| Example 8 | 15.24 | 68.14 | 56.92/0.24 |
| Example 9 | 11.21 | 80.21 | 504.81/0.83 |
| Example 10 | 9.41 | 43.27 | 28.11/0.30 |
| Example 11 | 17.01 | 80.67 | 251.48/0.56 |
| Example 12 | 6.94 | 80.67 | 31.02/0.45 |
As can be seen from table 1, the doxorubicin nanoparticles provided in examples 1 to 7 all have a drug loading rate higher than 20%, an encapsulation rate higher than 50%, a particle size between 50 and 120nm, and PDI less than 0.6, which indicates that the doxorubicin nanoparticles provided in examples 1 to 7 have higher drug loading rate and encapsulation rate, and a particle size between 50 and 120nm, have good biofilm penetration, and are beneficial for targeting tumor cells.
As can be seen from the comparison of examples 1 to 7 and examples 8 to 12, when the mass ratio of PGA, Cys and DOX is (1 to 3): (2-6): and (1-3), the adriamycin nano-particles with excellent comprehensive performance can be obtained more favorably. In addition, the particle size distribution diagram of the adriamycin nanoparticles provided in example 1 detected in a malvern laser particle sizer is shown in fig. 1, and as can be seen from fig. 1, the particle size distribution of the adriamycin nanoparticles provided in example 1 is 50-100nm, so that the adriamycin nanoparticles have excellent tumor cell targeting property.
Test example 2
Ultraviolet absorption spectrum tests were performed on the doxorubicin nanoparticle solution provided in example 1 and an aqueous solution of DOX provided in comparative example 1, respectively, and the obtained spectra are shown in fig. 2, wherein DOX represents the aqueous solution of DOX provided in comparative example 1, and DOX-PGA represents the doxorubicin nanoparticle solution provided in example 1; as can be seen from fig. 2, the doxorubicin nanoparticle solution provided in example 1 retained the characteristic absorption peak typical of doxorubicin, and the absorption peak at 480nm produced a significant red-shift due to the encapsulation of doxorubicin in the polyamino acid nanoparticles.
Test example 3
Brain glioma cells (U87) were seeded in 96-well plates (10)4One/well), after the doxorubicin nanoparticle solution provided in example 1 and the aqueous solution of DOX provided in comparative example 1 were respectively formulated into solutions with DOX doses of 0 μ g/m L, 1.25 μ g/m L, 2.5 μ g/m L, 5 μ g/m L, 10 μ g/m L and 20 μ g/m L, the solutions were respectively added to brain glioma cells for incubation for 24 hours, and then the cell viability was measured by CCK8 reagent and microplate reader, as shown in fig. 3, DOX represents the aqueous solution of DOX provided in comparative example 1, and DOX-PGA represents the doxorubicin nanoparticle solution provided in example 1.
As can be seen from fig. 3, the killing efficiency of the doxorubicin nanoparticles provided in example 1 and the killing efficiency of the doxorubicin solution provided in comparative example 1 are equivalent for the same DOX dose, which indicates that the effect of doxorubicin chemotherapy is not affected by loading doxorubicin in the polyamino acid nanoparticles.
Test example 4
Brain glioma cells (U87) were seeded in 96-well plates(104One/well), the doxorubicin nanoparticles provided in example 1 and the aqueous solution of DOX provided in proportion 1 were prepared into solutions with respective doses of DOX of 0 μ g/m L, 1.25 μ g/m L, 2.5 μ g/m L, 5 μ g/m L, 10 μ g/m L and 20 μ g/m L, and the solutions were added to the glioma cells, respectively, and after incubation for 3 hours, the glioma cells without the drug added were simultaneously used as a blank control group, and the cells in each well to which the drug solution was added and the cells in the blank control group were sonicated for 3 minutes (power of 1.5W/cm)2) After 24 hours, the cell survival rate is detected by a CCK8 reagent and a microplate reader, and the result is shown in FIG. 4, wherein Control (+) represents the ultrasonic treatment of the blank Control group, and DOX (+) represents the combined ultrasonic treatment of the aqueous solution of DOX provided in the comparative example 1; DOX-PGA (+) represents the doxorubicin nanoparticle solution provided in example 1 in combination with sonication.
As can be seen from fig. 4, by performing ultrasound, the killing efficiency of the doxorubicin nanoparticles provided in example 1 on tumor cells is significantly higher than that of the doxorubicin nanoparticles provided in comparative example 1, which indicates that the doxorubicin nanoparticles provided in example 1 have acoustic sensitivity, can implement acoustic-dynamic combination chemotherapy on tumor cells under the action of ultrasound, overcome the problem of tumor drug resistance, and significantly improve the anti-tumor therapeutic effect.
Test example 5
The doxorubicin nanoparticles provided in example 1 and the aqueous solution of DOX provided in comparative example 1 were each prepared as a solution having a DOX dose of 20 μ g/m L, and then the above solutions were placed in two 35 mm-diameter cell culture dishes, while the deionized water provided in comparative example 2 was placed in a third 35 mm-diameter cell culture dish, and then the active oxygen cluster fluorescent indicator SOSG was added to the three cell culture dishes, and then the solutions in the three dishes were subjected to sonication for 8 minutes (power of 1.5W/cm) respectively (power of 1.5W/cm)2) Taking 200 mu L solution from the three cell culture dishes respectively and placing the solution in a centrifuge tube within a certain ultrasonic time (0min, 0.5min, 1min, 2min, 3min, 5min, 8min), wherein the fluorescence imaging graph is shown in FIG. 5, wherein H2O represents deionized water provided in comparative example 2 and DOX represents an aqueous solution of DOX provided in comparative example 1; DOX-PGA represents the doxorubicin nanoparticles provided in example 1A pellet solution.
As can be seen from fig. 5, when the deionized water provided by comparative example 2 is subjected to short-time ultrasound, fluorescence cannot be generated, and only weak fluorescence can be generated as the ultrasound time is prolonged, whereas when the aqueous solution of DOX provided by comparative example 1 is subjected to short-time ultrasound, fluorescence which is stronger than that of comparative example 2 but weaker than that of example 1 can be generated as the ultrasound time is prolonged, whereas when the doxorubicin nanoparticles provided by example 1 are subjected to short-time ultrasound, fluorescence which is remarkably stronger than that of comparative example 1 can be generated as the ultrasound time is prolonged, which indicates that under the ultrasound action, the doxorubicin nanoparticles provided by example 1 generate a significantly higher number of active oxygen clusters than that of the DOX solution provided by comparative example 1, i.e. the doxorubicin nanoparticles provided by example 1 have significantly improved acoustic sensitivity by supporting doxorubicin on the polyamino acid nanoparticles, thereby effectively improving the anti-tumor curative effect.
Test example 6
The doxorubicin nanoparticles 2m L provided in example 1 were loaded into two dialysis bags of molecular weight 3500, each dialysis bag being 1m L, and then the two dialysis bags were placed into two centrifuge tubes with covers containing 25m L, PBS solution of ph7.4 and PBS solution of ph5.5, respectively, the two centrifuge tubes were placed into air bath shakers (temperature 37 ℃ and rotation speed 200rpm) and shaken, and samples containing DOX dialyzed out at 1m L were taken out of the two centrifuge tubes and filled with fresh PBS solution at appropriate time intervals (0.5h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h), and finally, the collected samples were subjected to quantitative analysis using a fluorescence spectrophotometer, and a doxorubicin release curve was plotted as shown in fig. 6, wherein ph7.4 represents the doxorubicin release curve of the doxorubicin nanoparticles provided in example 1 at ph7.4 (neutral) and the doxorubicin release curve of example 1.5 represents the doxorubicin release curve of the doxorubicin nanoparticles in ph5 (neutral) solution, and PBS curve of example 5.5 represents the doxorubicin release curve of the doxorubicin solution at ph5 (5).
As can be seen from fig. 6, the doxorubicin nanoparticles provided in example 1 released almost completely (release amount of 93%) at 4h in PBS solution at ph5.5 (acidic), whereas the doxorubicin nanoparticles provided in example 1 released only 33% at 24h in PBS solution at ph 7.4. This shows that the doxorubicin nanoparticles provided in example 1 have significantly higher doxorubicin release efficiency and release amount in the PBS solution at ph7.4 (neutral) than in the PBS solution at ph5.5 (acidic). This demonstrates that the doxorubicin nanoparticles provided in example 1 can be rapidly degraded under acidic conditions, and that a responsive controlled release of doxorubicin is achieved.
Finally, it should be noted that: the above embodiments are only used to illustrate the technical solution of the present invention, and not to limit the same; while the invention has been described in detail and with reference to the foregoing embodiments, it will be understood by those skilled in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some or all of the technical features may be equivalently replaced; and the modifications or the substitutions do not make the essence of the corresponding technical solutions depart from the scope of the technical solutions of the embodiments of the present invention.
Claims (10)
1. An adriamycin nanoparticle, which is characterized by comprising adriamycin and a nanoparticle carrier, wherein the adriamycin is loaded on the nanoparticle carrier.
2. The doxorubicin nanoparticle according to claim 1, wherein said nanoparticle carrier is selected from at least one of liposome, polyamino acid nanoparticle, polylactic-glycolic acid nanoparticle, gold nanocage and mesoporous silicon, preferably polyamino acid nanoparticle.
3. Doxorubicin nanoparticles according to claim 1, wherein said doxorubicin nanoparticles have a particle size of 20-150nm, preferably 50-100 nm.
4. A preparation method of adriamycin nanoparticles is characterized by comprising the following steps: uniformly mixing adriamycin and the nanoparticle carrier to enable the adriamycin to be loaded on the nanoparticle carrier to obtain adriamycin nanoparticles;
preferably, the nanoparticle carrier is a polyamino acid nanoparticle.
5. The method of claim 4, comprising the steps of: uniformly mixing a polyamino acid solution, an adriamycin solution and a cross-linking agent solution, so that polyamino acid and the cross-linking agent react, fold and cross-link to form polyamino acid nanoparticles, and meanwhile, adriamycin is loaded on the polyamino acid nanoparticles to obtain adriamycin nanoparticles;
preferably, a carboxyl activating agent is added into the polyamino acid solution for carboxyl activation, and then the mixture is uniformly mixed with the adriamycin solution and the cross-linking agent solution;
preferably, the carboxyl activating agent is EDC and/or NHS, preferably EDC and NHS;
further preferably, the mass ratio of EDC and NHS is (5-6): (3-4).
6. The preparation method according to claim 5, wherein the cross-linking agent is a diamino small molecule cross-linking agent, preferably cystamine dihydrochloride;
and/or, the polyamino acid is selected from one or more of polyglutamic acid, polyaspartic acid, polyalanine, polylysine and polyalanine and salts thereof, and is preferably polyglutamate.
7. The preparation method according to claim 6, wherein the mass ratio of the polyglutamate, the cystamine dihydrochloride and the adriamycin is (1-3): (2-6): (1-3), preferably 1:2: 1.
8. The method according to claim 5, wherein the polyamino acid solution is a PBS solution of polyamino acid having a concentration of (0.5-1.5) mg/m L, preferably 1mg/m L;
and/or the cystamine dihydrochloride solution is a cystamine dihydrochloride PBS solution, and the concentration of the cystamine dihydrochloride PBS solution is (0.5-1.5) mg/m L, preferably 1mg/m L;
and/or the adriamycin solution is a PBS (phosphate buffer solution) of adriamycin, and the concentration of the PBS of the adriamycin is (0.2-0.8) mg/m L, preferably 0.5mg/m L.
9. Use of the doxorubicin nanoparticles according to any one of claims 1-3 or the doxorubicin nanoparticles obtained by the preparation method according to any one of claims 4-8 for the preparation of a medicament for sonodynamic combination chemotherapy of tumors.
10. An acoustodynamic combined chemotherapy tumor drug, which is characterized by comprising the adriamycin nano-particle of any one of claims 1 to 3 or the adriamycin nano-particle obtained by the preparation method of any one of claims 4 to 8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811615253.4A CN111388447B (en) | 2018-12-27 | 2018-12-27 | Adriamycin nano-particles, preparation method and application thereof, and medicine for treating tumors by combining acoustic power with chemical therapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811615253.4A CN111388447B (en) | 2018-12-27 | 2018-12-27 | Adriamycin nano-particles, preparation method and application thereof, and medicine for treating tumors by combining acoustic power with chemical therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN111388447A true CN111388447A (en) | 2020-07-10 |
| CN111388447B CN111388447B (en) | 2022-06-21 |
Family
ID=71410687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811615253.4A Active CN111388447B (en) | 2018-12-27 | 2018-12-27 | Adriamycin nano-particles, preparation method and application thereof, and medicine for treating tumors by combining acoustic power with chemical therapy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111388447B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102813937A (en) * | 2012-06-12 | 2012-12-12 | 天津大学 | Hydrophobic drug containing polyelectrolyte complex, its preparation method and application thereof |
| US20140294983A1 (en) * | 2013-03-28 | 2014-10-02 | Bbs Nanotechnology Ltd. | Stable nanocomposition comprising doxorubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it |
| CN104491871A (en) * | 2014-12-02 | 2015-04-08 | 江南大学 | PH/reduction-sensitive nano microgel based on polyglutamic acid and cystamine |
-
2018
- 2018-12-27 CN CN201811615253.4A patent/CN111388447B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102813937A (en) * | 2012-06-12 | 2012-12-12 | 天津大学 | Hydrophobic drug containing polyelectrolyte complex, its preparation method and application thereof |
| US20140294983A1 (en) * | 2013-03-28 | 2014-10-02 | Bbs Nanotechnology Ltd. | Stable nanocomposition comprising doxorubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it |
| CN104491871A (en) * | 2014-12-02 | 2015-04-08 | 江南大学 | PH/reduction-sensitive nano microgel based on polyglutamic acid and cystamine |
Non-Patent Citations (4)
| Title |
|---|
| TSAI ET AL.: "Enhancement of the Cytotoxicity and Selectivity of Doxorubicin to Hepatoma Cells by Synergistic Combination of Galactose-Decorated γ-Poly(glutamic acid) Nanoparticles and Low-Intensity Ultrasound", 《LANGMUIR》 * |
| 刘文清等: "聚谷氨酸阿霉素前药的制备及性能研究", 《天津生物医学工程2012年学术年会论文摘要》 * |
| 吴鲁艳: "pH/还原响应性两性离子纳米颗粒的制备及药物控释研究", 《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》 * |
| 崔福德主编: "《药剂学 第2版》", 31 January 2011, 中国医药科技出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN111388447B (en) | 2022-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xie et al. | O2-Cu/ZIF-8@ Ce6/ZIF-8@ F127 composite as a tumor microenvironment-responsive nanoplatform with enhanced photo-/chemodynamic antitumor efficacy | |
| An et al. | ROS-augmented and tumor-microenvironment responsive biodegradable nanoplatform for enhancing chemo-sonodynamic therapy | |
| CN111643673B (en) | Tumor-targeted nano-drug simultaneously encapsulating photosensitizer and protein and application thereof | |
| Qin et al. | pH-responsive polymer-stabilized ZIF-8 nanocomposites for fluorescence and magnetic resonance dual-modal imaging-guided chemo-/photodynamic combinational cancer therapy | |
| CN108524935B (en) | Quercetin drug delivery system based on copper sulfide-metal organic framework material | |
| Ding et al. | A multimodal Metal-Organic framework based on unsaturated metal site for enhancing antitumor cytotoxicity through Chemo-Photodynamic therapy | |
| Verma et al. | Covalent immobilization of doxorubicin in glycine functionalized hydroxyapatite nanoparticles for pH-responsive release | |
| CN101785759B (en) | Nanoparticle for embedding medicinal Adriamycin as well as preparation method and application thereof | |
| CN113679845A (en) | Preparation method and application of polycarbonate drug-loaded nano-chemotherapy sensitizer based on nitric oxide | |
| CN115708813A (en) | Multifunctional manganese-based nanoparticles and preparation method and medical application thereof | |
| CN114652833A (en) | PH/near infrared light dual-responsiveness nano drug delivery system for targeted multi-mode cooperative therapy and preparation method and application thereof | |
| Cao et al. | Ultrasound-assisted continuous-flow synthesis of PEGylated MIL-101 (Cr) nanoparticles for hematopoietic radioprotection | |
| Vimala et al. | Selenium tethered mesoporous silica nanocomposite enhances drug delivering efficiency to target breast cancer | |
| CN104147608B (en) | Lithium amide soapstone nano particles modified by polyethylene glycol-folic acid as well as preparation and application of lithium amide soapstone nano particles | |
| CN105902519B (en) | A kind of pH and glucose dual responsiveness pharmaceutical carrier and its preparation and application | |
| CN111388447B (en) | Adriamycin nano-particles, preparation method and application thereof, and medicine for treating tumors by combining acoustic power with chemical therapy | |
| CN115252775B (en) | Tumor nano-drug based on polyethyleneimine and Prussian blue, and preparation method and application thereof | |
| CN111228513A (en) | Amorphous calcium carbonate composite nano-drug with effect of inducing tumor cell iron death and preparation method thereof | |
| CN115192708A (en) | Nano composite material loaded with anti-tumor drug, nano drug-loaded system, preparation and application | |
| CN114601936A (en) | Tumor-targeted near-infrared light-responsive nitric oxide nano generator, preparation method and application thereof | |
| JP6868306B2 (en) | Cell introduction agent | |
| Zuo et al. | pH-responsive nanocatalyst for enhancing cancer therapy via H 2 O 2 homeostasis disruption and disulfiram sensitization | |
| US20150072938A1 (en) | Cationic graft-copolymer for drug delivery system | |
| CN115364215B (en) | Platinum medicine carbon nano dot, preparation method thereof, carbon nano dot protein complex and application | |
| CN110384703A (en) | Metal based on 6- thioguanine-drug coordination Nano medication and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |